[{"id":"55b1a0de-6575-4213-92f4-3ad23c6cc089","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150403","created_at":"2025-09-06T13:44:19.461Z","updated_at":"2025-09-06T13:44:19.461Z","phase":"Phase 2","brief_title":"A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150403","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-09-02"},{"id":"dacc9da3-7f50-4fcd-b6ab-f82afa578e33","acronym":"","url":"https://clinicaltrials.gov/study/NCT07025850","created_at":"2025-06-21T13:17:03.504Z","updated_at":"2025-06-21T13:17:03.504Z","phase":"Phase 1/2","brief_title":"Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT07025850","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-06-18"},{"id":"ddb28914-edb2-4733-8bbd-06431d3d7e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856837","created_at":"2025-09-07T01:48:45.276Z","updated_at":"2025-09-07T01:48:45.276Z","phase":"Phase 2","brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","source_id_and_acronym":"NCT06856837","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-04"},{"id":"111c1a17-fe9b-4de2-8802-129cd4e4d500","acronym":"LEAP-006","url":"https://clinicaltrials.gov/study/NCT03829319","created_at":"2021-01-17T17:11:51.730Z","updated_at":"2025-02-25T13:35:12.715Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","source_id_and_acronym":"NCT03829319 - LEAP-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 761","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"e11728e3-5408-43ee-84fa-396a29b7eccd","acronym":"LEAP-007","url":"https://clinicaltrials.gov/study/NCT03829332","created_at":"2021-01-18T18:54:37.440Z","updated_at":"2025-02-25T13:35:13.317Z","phase":"Phase 3","brief_title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)","source_id_and_acronym":"NCT03829332 - LEAP-007","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 623","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 05/19/2021","primary_completion_date":" 05/19/2021","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2025-02-14"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"9b2dd962-db93-43b8-b077-57bd460b2d26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996823","created_at":"2021-08-09T13:53:12.104Z","updated_at":"2025-02-25T15:19:13.745Z","phase":"Phase 2","brief_title":"Axitinib + Ipilimumab in Advanced Melanoma","source_id_and_acronym":"NCT04996823","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 03/29/2026","primary_completion_date":" 03/29/2026","study_txt":" Completion: 03/29/2027","study_completion_date":" 03/29/2027","last_update_posted":"2025-02-12"},{"id":"a46eecea-cdfb-4325-ac71-c96ea8e37386","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823311","created_at":"2023-04-21T15:04:25.336Z","updated_at":"2025-02-25T15:20:26.716Z","phase":"Phase 3","brief_title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05823311","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"f87d079d-5408-46e1-abc8-978710f92fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05532059","created_at":"2022-09-08T13:55:00.765Z","updated_at":"2025-02-25T15:27:37.097Z","phase":"Phase 2","brief_title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05532059","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-10"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"f5cb8c43-6865-4b75-b3de-bf63f4e8a4e4","acronym":"LEAP-015","url":"https://clinicaltrials.gov/study/NCT04662710","created_at":"2021-01-19T20:42:39.419Z","updated_at":"2025-02-25T13:35:41.688Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","source_id_and_acronym":"NCT04662710 - LEAP-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 10/29/2024","primary_completion_date":" 10/29/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-06"},{"id":"caa0f388-4c19-438d-9bce-36b37f87c82f","acronym":"NRG-GY004","url":"https://clinicaltrials.gov/study/NCT02446600","created_at":"2021-01-18T11:43:37.532Z","updated_at":"2025-02-25T15:06:35.061Z","phase":"Phase 3","brief_title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02446600 - NRG-GY004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 579","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 02/23/2020","primary_completion_date":" 02/23/2020","study_txt":" Completion: 08/23/2025","study_completion_date":" 08/23/2025","last_update_posted":"2025-02-03"},{"id":"739976b0-7ec7-4952-93a7-789eca0ef355","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114421","created_at":"2021-11-10T14:12:47.360Z","updated_at":"2025-02-25T17:25:20.145Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients","source_id_and_acronym":"NCT05114421","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-31"},{"id":"66e980f4-fc20-4c1f-b295-732ba31ba490","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345265","created_at":"2021-01-18T11:09:11.903Z","updated_at":"2025-02-25T17:29:14.435Z","phase":"Phase 2","brief_title":"Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02345265","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 07/07/2022","primary_completion_date":" 07/07/2022","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2025-01-30"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"d09ef236-9ffc-468c-9ac9-80033eba5a47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05147558","created_at":"2021-12-07T13:53:36.843Z","updated_at":"2025-02-25T16:17:01.717Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma","source_id_and_acronym":"NCT05147558","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/23/2021","start_date":" 12/23/2021","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-01-27"},{"id":"676a91c9-2aba-4008-872e-5a9b996188c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791083","created_at":"2025-02-25T18:40:00.939Z","updated_at":"2025-02-25T18:40:00.939Z","phase":"Phase 2","brief_title":"Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","source_id_and_acronym":"NCT06791083","lead_sponsor":"First Affiliated Hospital of Fujian Medical University","biomarkers":" CD8 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-01-24"},{"id":"eccae38b-1886-4206-b6f1-ab2c523e9706","acronym":"BAROCCO","url":"https://clinicaltrials.gov/study/NCT03314740","created_at":"2021-01-18T16:22:11.917Z","updated_at":"2025-02-25T14:58:26.251Z","phase":"Phase 2","brief_title":"Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib","source_id_and_acronym":"NCT03314740 - BAROCCO","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2025-01-10"},{"id":"6d8ce925-047e-4380-9392-20b7805d056d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955743","created_at":"2021-07-09T12:57:14.611Z","updated_at":"2025-02-25T16:16:25.608Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma","source_id_and_acronym":"NCT04955743","lead_sponsor":"Yale University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-12-24"},{"id":"05e655b5-ceb5-4cfa-ba00-4d49783fd7fb","acronym":"LEAP-003","url":"https://clinicaltrials.gov/study/NCT03820986","created_at":"2021-01-18T18:52:34.602Z","updated_at":"2025-02-25T13:35:12.099Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","source_id_and_acronym":"NCT03820986 - LEAP-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 674","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 01/18/2023","primary_completion_date":" 01/18/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-12-02"}]